Dan Ma, Ping Liu, Chujiao Hu, Zhen Zhou, Ping Wang, Yan Wang, Yaming Zhang, Yunsheng Ran, Pinghao Li, Jiangyuan Zhao, Jishi Wang, Chengliang Zhang, Lei Tang
Oncogene 2023 JanDrug resistance from BCR-ABL tyrosine kinase inhibitors (TKIs) and other chemotherapeutics results in treatment failure and disease progression in chronic myeloid leukemia (CML). However, the mechanism is still uncertain. In this study, we investigated the role of angiopoietin-1 (ANG-1) as a potential prognostic factor for drug resistance in CML. Both intracellular and secretory ANG-1 (iANG-1 and sANG-1) were overexpressed in multidrug-resistant CML samples. The IC50 value was higher in primary CD34+ CD38- cells with more ANG-1. Silencing ANG-1significantly sensitized three TKI-resistant CML cell lines to imatinib (IM) while recombinant human ANG-1 failed to retain cell survival in vitro. This indicated the important role of iANG-1 as opposed to sANG-1 in CML drug resistance. Moreover, a similar effect was observed in xenograft mice models bearing ANG-1-silenced CML cells. Subsequently, pathway analysis and protein validation experiments showed activation of the JAK/STAT pathway and augmentation of STAT5a phosphorylation in ANG-1 restored CML cells. Upstream Src phosphorylation, which plays a crucial role in CML drug resistance, was also upregulated as a key event in iANG-1-related JAK/STAT pathway activation. In conclusion, our study elucidated a new BCR-ABL independent molecular mechanism induced by intracytoplasmic ANG-1 overexpression as a potential strategy for overcoming CML resistance. © 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Dan Ma, Ping Liu, Chujiao Hu, Zhen Zhou, Ping Wang, Yan Wang, Yaming Zhang, Yunsheng Ran, Pinghao Li, Jiangyuan Zhao, Jishi Wang, Chengliang Zhang, Lei Tang. Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia. Oncogene. 2023 Jan;42(2):124-137
PMID: 36385374
View Full Text